Presentation and outcomes of hepatocellular carcinoma patients at a western centre

HPB

Volumn 13, Issue 10, 2011, Pages 712-722

  Kitisin, Krit ^a,b   Packiam, Vignesh ^a   Steel, Jennifer ^a,c   Humar, Abhinav ^c   Gamblin, T Clark ^d   Geller, David A ^a   Marsh, J Wallis ^a   Tsung, Allan ^a,c  

^a Department of Surgery   (United States)

^b Division of Surgical Oncology   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

chemotherapy; hepatocellular carcinoma; outcomes; palliation; resection; transplant

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; END STAGE LIVER DISEASE; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; RADIOFREQUENCY ABLATION; SYSTEMIC THERAPY;

EID: 80053564459     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2011.00362.x     Document Type: Article

References (67)

1. Bosch FX, Ribes J, Diaz M, Cleries R,. (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 5 (Suppl. 1): S5-S16. (Pubitemid 39423365)
2. Parkin DM,. (2001) Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543. (Pubitemid 33586866)
3. El-Serag HB, Mason AC,. (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750. (Pubitemid 29114292)
4. Mor E, Kaspa RT, Sheiner P, Schwartz M,. (1998) Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 129: 643-653. (Pubitemid 28480821)
5. Blumberg BS, Larouze B, London WT, Werner B, Hesser JE, Millman I, et al,. (1975) The relation of infection with the hepatitis B agent to primary hepatic carcinoma. Am J Pathol 81: 669-682.
6. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al,. (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328: 1797-1801. (Pubitemid 23174709)
7. Llovet JM, Fuster J, Bruix J,. (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434-1440.
8. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al,. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699. (Pubitemid 26079803)
9. Jonas S, Herrmann M, Rayes N, Berg T, Radke C, Tullius S, et al,. (2001) Survival after liver transplantation for hepatocellular carcinoma in cirrhosis according to the underlying liver disease. Transplant Proc 33: 3444-3445. (Pubitemid 34042642)
10. Bismuth H, Majno PE, Adam R,. (1999) Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 19: 311-322.
11. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A,. (1993) Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218: 145-151. (Pubitemid 23229140)
12. Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, et al,. (1998) Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 27: 1572-1577. (Pubitemid 28264681)
13. Roberts JP,. (2005) Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 11 (Suppl. 2): S45-S46. (Pubitemid 43072614)
14. El-Serag HB,. (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 5 (Suppl. 1): S27-S34. (Pubitemid 39423367)
15. Charpentier KP, Cheah YL, Machan JT, Miner T, Morrissey P, Monaco A,. (2008) Intention to treat survival following liver transplantation for hepatocellular carcinoma within a donor service area. HPB (Oxford) 10: 412-415.
16. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al,. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739. (Pubitemid 34607087)
17. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al,. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224: 47-54. (Pubitemid 34680374)
18. Llovet JM, Bruix J,. (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442. (Pubitemid 36152543)
19. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al,. (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9: 1920-1928.
20. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al,. (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140: 497-507. e2.
21. Carr BI, Kondragunta V, Buch SC, Branch RA,. (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116: 1305-1314.
22. Heckman JT, Devera MB, Marsh JW, Fontes P, Amesur NB, Holloway SE, et al,. (2008) Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 15: 3169-3177.
23. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al,. (2011) Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253: 453-469.
24. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, et al,. (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248: 617-625.
25. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al,. (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8: 2547-2557.
26. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al,. (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40: 1352-1360. (Pubitemid 39657009)
27. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K, et al,. (1993) Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol 160: 1023-1028. (Pubitemid 23141242)
28. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al,. (1995) Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197: 101-108.
29. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al,. (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228: 235-240. (Pubitemid 36736097)
30. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al,. (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243: 321-328. (Pubitemid 43327762)
31. Cho YK, Kim JK, Kim MY, Rhim H, Han JK,. (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49: 453-459.
32. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC,. (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 127: 1714-1723.
33. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al,. (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130. (Pubitemid 41002049)
34. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al,. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
35. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al,. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
36. Bruix J, Llovet JM,. (2010) Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis 30: 1-2.
37. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, et al,. (2011) Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 253: 745-758.
38. Mok KT, Wang BW, Lo GH, Liang HL, Liu SI, Chou NH, et al,. (2003) Multimodality management of hepatocellular carcinoma larger than 10 cm. J Am Coll Surg 197: 730-738.
39. Takano S, Watanabe Y, Ohishi H, Kono S, Nakamura M, Kubota N, et al,. (2000) Multimodality treatment for patients with hepatocellular carcinoma: a single institution retrospective series. Eur J Surg Oncol 26: 67-72. (Pubitemid 30102826)
40. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al,. (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4: 439-474.
41. Song P, Tang W, Tamura S, Hasegawa K, Sugawara Y, Dong J, et al,. (2010) The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation. Biosci Trends 4: 283-287.
42. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al,. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10: 1111-1118.
43. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, et al,. (2010) Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 40: 667-685.
44. Geller DA, Tsung A, Marsh JW, Dvorchik I, Gamblin TC, Carr BI,. (2006) Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. J Gastrointest Surg 10: 63-68. (Pubitemid 41820589)
45. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N, et al,. (2003) Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 97: 1042-1050. (Pubitemid 36173156)
46. Carr BI,. (2004) Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2 (Suppl. 1): S107-S110. (Pubitemid 38240109)
47. Trotter JF, Osgood MJ,. (2004) MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 291: 1871-1874. (Pubitemid 38509500)
48. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al,. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41: 707-716. (Pubitemid 40462931)
49. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al,. (2005) Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54: 411-418. (Pubitemid 40299100)
50. Yeh CN, Lee WC, Chen MF,. (2003) Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 10: 1070-1076.
51. Yuen MF, Hou JL, Chutaputti A,. (2009) Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24: 346-353.
52. Lau WY, Lai EC,. (2007) Salvage surgery following downstaging of unresectable hepatocellular carcinoma-a strategy to increase resectability. Ann Surg Oncol 14: 3301-3309. (Pubitemid 350160117)
53. Lau WY, Lai EC,. (2009) The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 249: 20-25.
54. Hsu C, Huang CL, Hsu HC, Lee PH, Wang SJ, Cheng AL,. (2002) HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 94: 415-420. (Pubitemid 34081371)
55. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M,. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.
56. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al,. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171. (Pubitemid 34454013)
57. Bruix J, Sala M, Llovet JM,. (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 5 (Suppl. 1): S179-S188. (Pubitemid 39423386)
58. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al,. (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469. (Pubitemid 44142456)
59. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al,. (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16: 1627-1639. (Pubitemid 44431160)
60. Bruix J, Sherman M,. (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. (Pubitemid 43112690)
61. Capussotti L, Ferrero A, Vigano L, Polastri R, Tabone M,. (2009) Liver resection for HCC with cirrhosis: surgical perspectives out of EASL/AASLD guidelines. Eur J Surg Oncol 35: 11-15.
62. Cabibbo G, Latteri F, Antonucci M, Craxi A,. (2009) Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 6: 159-169.
63. Lee HS,. (2007) Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: the controversies continue. Dig Dis 25: 296-298.
64. Christians KK, Pitt HA, Rilling WS, Franco J, Quiroz FA, Adams MB, et al,. (2001) Hepatocellular carcinoma: multimodality management. Surgery 130: 554-559. discussion 9-60.
65. Roayaie S, Haim MB, Emre S, Fishbein TM, Sheiner PA, Miller CM, et al,. (2000) Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol 7: 764-770.
66. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al,. (2006) Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101: 524-532. (Pubitemid 43340928)
67. Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, et al,. (2009) Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 43: 482-488.